Related Experiment Video
Updated: Feb 12, 2026

Quantifying the Antifungal Activity of Peptides Against Candida albicans
Published on: January 13, 2023
Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
M Salem1, T Reichlin2, D Fasel3
1Department of Clinical Pharmacology and Toxicology, University & University Hospital Basel, Switzerland.
Abstract:
Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study were therefore to identify all cases of torsade de pointes associated with systemic azole antifungal use reported to the WHO monitoring centre (Uppsala, Sweden) and to determine the latency times between commencing the azole and developing torsade de pointes. Methods: Investigator-driven, retrospective, descriptive analysis of post-marketing pharmacovigilance data regarding systemic azole antifungal agents and the development of torsade de pointes reported to the WHO monitoring centre 1995-2015. Results: 191 cases were reported as follows: fluconazole 130, itraconazole 22, ketoconazole 5, posaconazole 1, voriconazole 33. More than half of all cases involved concomitant suspected or interacting drugs. The median latency times between starting the azole and developing torsade de pointes ranged from 1 (posaconazole) - 9.5 days (itraconazole), range <1-250). Conclusions: Clinicians should be aware of these features of azole-associated torsade de pointes, avoid interacting drugs if at all possible and monitor at-risk patients.
Insights
Azole antifungal drugs can cause torsade de pointes, a heart rhythm disorder. This study analyzed 191 cases, revealing median latency times from drug initiation to torsade de pointes onset.
Area of Science:
- Pharmacovigilance
- Cardiology
- Infectious Diseases
Background:
- Limited literature exists on torsade de pointes (TdP) induced by azole antifungal agents.
- The latency period between azole initiation and TdP development is poorly understood.
Purpose of the Study:
- To identify TdP cases linked to systemic azole antifungal use reported to the WHO.
- To determine the time lag between starting azoles and the onset of TdP.
Main Methods:
- Retrospective, descriptive analysis of pharmacovigilance data from 1995-2015.
- Data sourced from the WHO monitoring centre (Uppsala, Sweden).
Main Results:
- 191 TdP cases associated with azoles were reported: fluconazole (130), voriconazole (33), itraconazole (22), ketoconazole (5), posaconazole (1).
- Over half of cases involved concomitant interacting drugs.
- Median latency times ranged from 1 day (posaconazole) to 9.5 days (itraconazole).
Conclusions:
- Clinicians must recognize azole-associated TdP risks.
- Avoid drug interactions and monitor high-risk patients.
- Awareness of latency times is crucial for timely intervention.
Related Concept Videos
Global Regulatory Systems
Spontaneity
Global Climate Change
Survey Safety
Household Wiring And Electrical Safety
Data Reporting and Recording

